Back to User profile » Dr Srihari Gopal
Papers published by Dr Srihari Gopal:
Comparing Relapse Rates in Real-World Patients with Schizophrenia Who Were Adequately versus Not Adequately Treated with Paliperidone Palmitate Once-Monthly Injections Before Transitioning to Once-Every-3-Months Injections
Turkoz I, Daskiran M, Starr HL, Najarian D, Lopena O, Obando C, Keenan A, Benson C, Gopal S
Neuropsychiatric Disease and Treatment 2022, 18:1927-1937
Published Date: 30 August 2022
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
Li G, Keenan A, Daskiran M, Mathews M, Nuamah I, Orman C, Joshi K, Singh A, Godet A, Pungor K, Gopal S
Patient Preference and Adherence 2021, 15:2239-2248
Published Date: 2 October 2021
Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
O'Donnell A, Rao S, Turkoz I, Gopal S, Kim E
Neuropsychiatric Disease and Treatment 2021, 17:1-9
Published Date: 6 January 2021
Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
Lambert M, Sanchez P, Bergmans P, Gopal S, Mathews M, Wooller A, Pungor K
Neuropsychiatric Disease and Treatment 2020, 16:3197-3208
Published Date: 23 December 2020
Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire
Blackwood C, Sanga P, Nuamah I, Keenan A, Singh A, Mathews M, Gopal S
Patient Preference and Adherence 2020, 14:1093-1102
Published Date: 2 July 2020
Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
Mathews M, Gopal S, Singh A, Nuamah I, Pungor K, Tan W, Soares B, Kim E, Savitz AJ
Neuropsychiatric Disease and Treatment 2020, 16:1533-1542
Published Date: 19 June 2020
Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
Gopal S, Gogate J, Pungor K, Kim E, Singh A, Mathews M
Neuropsychiatric Disease and Treatment 2020, 16:681-690
Published Date: 6 March 2020
Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU
Neuropsychiatric Disease and Treatment 2019, 15:1365-1379
Published Date: 21 May 2019
Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Hargarter L
Neuropsychiatric Disease and Treatment 2019, 15:587-602
Published Date: 21 February 2019
Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
Mathe}ws M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S
Neuropsychiatric Disease and Treatment 2018, 14:2807-2816
Published Date: 25 October 2018
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ
Neuropsychiatric Disease and Treatment 2017, 13:2193-2207
Published Date: 17 August 2017
Physician and patient benefit–risk preferences from two randomized long-acting injectable antipsychotic trials
Katz EG, Hauber B, Gopal S, Fairchild A, Pugh A, Weinstein RB, Levitan BS
Patient Preference and Adherence 2016, 10:2127-2139
Published Date: 21 October 2016
Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
Zhang H, Li H, Liu Y, Wu C, Wu Q, Nuamah I, Shi J, Xie S, Wang G, Gopal S
Neuropsychiatric Disease and Treatment 2016, 12:69-77
Published Date: 8 January 2016
Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
Gopal S, Liu Y, Alphs L, Savitz A, Nuamah I, Hough D
Neuropsychiatric Disease and Treatment 2013, 9:1381-1392
Published Date: 20 September 2013
Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
Samtani MN, Nuamah I, Gopal S, Remmerie B, Sliwa JK, Alphs L
Neuropsychiatric Disease and Treatment 2013, 9:721-730
Published Date: 20 May 2013
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
Srihari Gopal, Joris Berwaerts, Isaac Nuamah, et al
Neuropsychiatric Disease and Treatment 2011, 7:93-101
Published Date: 8 March 2011